EPS for Heron Therapeutics, Inc. (HRTX) Expected At $-0.85 as of May, 9

April 17, 2018 - By Jenna Rose

On May, 9 WallStreet awaited Heron Therapeutics, Inc. (NASDAQ:HRTX)’s earnings release, RTT reports. Analysts predict 15.00 % diference or $-0.85 from the $-1 EPS from 2017. Last quarter $-1.09 earnings per share was reported. Analysts sees -22.02 % EPS growth this quarter. The stock decreased 1.31% or $0.4 during the last trading session, reaching $30.2.Heron Therapeutics, Inc. has volume of 860,133 shares. Since April 17, 2017 HRTX has risen 87.03% and is uptrending. HRTX outperformed the S&P 500 by 75.48%.

Heron Therapeutics, Inc. (NASDAQ:HRTX) Ratings Coverage

In total 10 analysts cover Heron Therapeutics (NASDAQ:HRTX). “Buy” rating has 10, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 21 are the (NASDAQ:HRTX)’s analyst reports since October 31, 2017 according to StockzIntelligence Inc. On Tuesday, March 27 the stock of Heron Therapeutics, Inc. (NASDAQ:HRTX) earned “Buy” rating by Oppenheimer. On Tuesday, November 7 the rating was maintained by Mizuho with “Buy”. On Tuesday, January 16 the stock of Heron Therapeutics, Inc. (NASDAQ:HRTX) earned “Buy” rating by Cowen & Co. On Monday, March 19 Oppenheimer maintained the shares of HRTX in report with “Buy” rating. On Monday, March 19 the rating was maintained by Cantor Fitzgerald with “Buy”. In Wednesday, January 31 report Cantor Fitzgerald maintained the stock with “Buy” rating. On Thursday, December 14 the company was maintained by Oppenheimer. On Wednesday, December 6 the company was maintained by Cowen & Co. On Friday, November 10 the stock of Heron Therapeutics, Inc. (NASDAQ:HRTX) has “Buy” rating given by Oppenheimer. In Thursday, April 5 report Evercore initiated it with “Buy” rating and $5600 target.

Heron Therapeutics, Inc., a biotechnology company, engages in developing medicines to address unmet medical needs.The company has $2.13 billion market cap. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single subcutaneous injection.Currently it has negative earnings. It offers SUSTOL extended-release injection for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens.

Heron Therapeutics, Inc. (NASDAQ:HRTX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.